A5064209980- Pancreatic and Hepatic Oncology Research
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Cancer-related Molecular Pathways
- Chemokine receptors and signaling
- Cancer Mechanisms and Therapy
- Lymphoma Diagnosis and Treatment
- Cancer Research and Treatments
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- PI3K/AKT/mTOR signaling in cancer
- HER2/EGFR in Cancer Research
- Chronic Lymphocytic Leukemia Research
- Estrogen and related hormone effects
- Esophageal Cancer Research and Treatment
- Angiogenesis and VEGF in Cancer
University of Florida Health
2021-2025
Massachusetts General Hospital
2024-2025
Harvard University
2012-2025
University of Florida
2021-2025
UF Health Cancer Center
2021-2025
Florida College
2022-2024
National Center for Advancing Translational Sciences
2023
National Institutes of Health
2023
Rhode Island Hospital
2018-2022
Providence College
2018-2022
Highlights•CXCR4 mediates extra-medullary multiple myeloma (MM)•CXCR4 enhances EMT-like phenotype acquisition in MM•Ulocuplumab inhibits MM cell dissemination and EMT MMSummaryExtra-medullary disease (EMD) (MM) is associated with poor prognosis resistance to chemotherapy. However, molecular alterations that lead EMD have not been well defined. We developed bone marrow (BM)- EMD-prone syngeneic lines; identified epithelial-to-mesenchymal transition (EMT) transcriptional patterns were...
Abstract Oncogenic mouse double minute 2 homolog (MDM2) is an E3-ubiquitin ligase that facilitates proteasomal degradation of p53. MDM2 amplification occurs in cancer and has been implicated accelerated tumor growth, known as hyper-progression, following immune-checkpoint therapy. also predicts poor response to inhibitors. We sought evaluate the role T-cell-mediated immune resistance. Ovarian clear cell carcinoma lines carrying wild-type p53 with low/high expression were investigated a...
Despite recent therapeutic advancements, outcomes for advanced hepatocellular carcinoma (HCC) remain unsatisfactory, highlighting the need novel treatments. The CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology offers innovative treatment approaches, involving genetic manipulation of either cancer cells or adoptive T to combat HCC. This review comprehensively assesses applications systems in HCC treatment, focusing on vivo targeting and development...
Abstract The diagnosis of parenchymal central nervous system (CNS) invasion and prediction risk for future CNS recurrence are major challenges in the management aggressive lymphomas, accurate biomarkers needed to supplement clinical predictors. For this purpose, we studied results a next-generation sequencing (NGS)–based assay that detects tumor-derived DNA clonotypic immunoglobulin gene rearrangements cerebrospinal fluid (CSF) patients with lymphomas. Used as diagnostic tool, NGS-minimal...
Background: Gallbladder carcinoma (GBC) is a rare, aggressive malignancy comprising 0.5% of gastrointestinal cancers. It has poor survival outcomes due to its insidious onset, lack standardized screening, and limited therapies. Advanced-stage diagnosis with liver, lymph node, peritoneal metastasis common, while bone rare. The knowledge on in GBC case reports small series, clinical significance largely unexplored. Methods: study extracted the demographic variables patients metastatic (M1)...
839 Background: Circulating tumor DNA (ctDNA) is a promising tool for monitoring treatment response but challenged by pan-cancer quantification and consistent outcome correlations. Northstar Response (NSR) quantifies >500 cancer specific methylated loci, offering reflection of disease burden clinical response. Methods: We present prospective observational study to evaluate the utility NSR. Patients with advanced GI cancers had serial ctDNA assessed at baseline during systemic correlations...